Trials / Completed
CompletedNCT00150618
Safety and Efficacy of SPD503 in Treating ADHD in Children and Adolescents Aged 6-17
A Phase III, Randomized, Double-Blind, Multi-Center, Parallel-Group, Placebo-Controlled Safety and Efficacy Study of SPD503 in Children and Adolescents Aged 6-17 With Attention Deficit Hyperactivity Disorder (ADHD)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 324 (actual)
- Sponsor
- Shire · Industry
- Sex
- All
- Age
- 6 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the efficacy of SPD503 compared to placebo in the treatment of children and adolescents aged 6-17 with ADHD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SPD503 (1 mg) | |
| DRUG | SPD503 (2 mg) | |
| DRUG | SPD503 (3 mg) | |
| DRUG | SPD503 (4 mg) | |
| DRUG | Placebo |
Timeline
- Start date
- 2004-03-30
- Primary completion
- 2004-10-07
- Completion
- 2004-10-07
- First posted
- 2005-09-08
- Last updated
- 2021-06-10
- Results posted
- 2009-10-15
Source: ClinicalTrials.gov record NCT00150618. Inclusion in this directory is not an endorsement.